Bowen Joslin M, Perry Anamarija M, Laurini Javier A, Smith Lynette M, Klinetobe Kimberly, Bast Martin, Vose Julie M, Aoun Patricia, Fu Kai, Greiner Timothy C, Chan Wing C, Armitage James O, Weisenburger Dennis D
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
Br J Haematol. 2014 Jul;166(2):202-8. doi: 10.1111/bjh.12880. Epub 2014 Apr 4.
Few studies have examined the value of a mandatory second review of outside pathology material for haematological malignancies. Therefore, we compared diagnoses on biopsies referred to an academic medical centre to determine the rate and therapeutic impact of revised diagnoses resulting from a second review. We reviewed 1010 cases referred for lymphoma during 2009-2010. For each case, referral diagnosis and second review diagnosis were compared. Revised diagnoses were grouped into major and minor discrepancies and all major discrepancies were reviewed by a haematologist to determine the effect the diagnostic change would have on therapy. There was no change in diagnosis in 861 (85·2%) cases. In 149 (14·8%) cases, second review resulted in major diagnostic change, of which 131 (12·9%) would have resulted in a therapeutic change. The highest rates of revision were for follicular, high-grade B-cell, and T-cell lymphomas. We found higher rates of major discrepancy in diagnoses from non-academic centres (15·8%) compared to academic centres (8·5%; P = 0·022), and in excisional biopsies (17·9%) compared to smaller biopsies (9·6%; P = 0·0003). Mandatory review of outside pathology material prior to treatment of patients for lymphoma will identify a significant number of misclassified cases with a major change in therapy.
很少有研究探讨对血液系统恶性肿瘤的外部病理材料进行强制二次审查的价值。因此,我们比较了转诊至一所学术医疗中心的活检诊断结果,以确定二次审查导致的诊断修正率及其对治疗的影响。我们回顾了2009年至2010年期间转诊来诊断淋巴瘤的1010例病例。对每例病例的转诊诊断和二次审查诊断进行比较。将修正诊断分为主要差异和次要差异,所有主要差异均由血液科医生进行审查,以确定诊断改变对治疗的影响。861例(85.2%)病例诊断无变化。149例(14.8%)病例经二次审查后诊断有重大改变,其中131例(12.9%)会导致治疗改变。修正率最高的是滤泡性、高级别B细胞和T细胞淋巴瘤。我们发现,与学术中心(8.5%;P = 0.022)相比,非学术中心诊断的主要差异率更高(15.8%),与小活检(9.6%;P = 0.0003)相比,切除活检的主要差异率更高(17.9%)。在对淋巴瘤患者进行治疗前对外部病理材料进行强制审查,将发现大量分类错误且治疗有重大改变的病例。